Our GMP Oligonucleotide Manufacturing Service supports pharmaceutical companies, biotechnology innovators, nucleic acid drug developers, and research organizations that need controlled production of DNA, RNA, and chemically modified oligonucleotides for advanced development programs. Once a sequence moves beyond small exploratory synthesis, project risk shifts toward process robustness, impurity control, purification scalability, analytical release planning, raw material management, and batch documentation. GMP oligonucleotide manufacturing requires coordinated control of synthesis, scale-up, purification, analytical characterization, and supply planning to support reliable development-stage production.
Our platform integrates sequence and CMC-oriented feasibility assessment, solid-phase oligonucleotide synthesis, scale-up planning, downstream purification, analytical characterization, and documentation support for GMP-focused oligonucleotide programs. We support single-stranded and duplex oligonucleotides, phosphorothioate and mixed-backbone designs, selected terminal and internal modifications, and development-stage conjugated formats, with manufacturing strategies aligned to molecule class, batch size, quality targets, and downstream program requirements.
Process Robustness: A sequence that performs well at bench scale may not behave predictably during larger manufacturing campaigns. Coupling efficiency, deprotection behavior, cleavage conditions, and intermediate handling all need to be translated into a reproducible process window. We support process definition work that improves batch-to-batch consistency before scale becomes a cost and quality problem.
Purity and Impurity Control: Oligonucleotide manufacturing often involves balancing purity targets with practical yield, especially for longer sequences, phosphorothioates, and heavily modified constructs. Our team designs fit-for-purpose purification strategies and integrates oligo analysis and purification planning early so that related species, shortmers, and process-derived impurities can be managed more efficiently.
Complex Chemistry: GMP oligo programs frequently involve base, sugar, backbone, linker, or terminal modifications that change synthesis behavior and downstream recovery. Our development teams combine sequence review with DNA/RNA modification planning to address chemistry-specific challenges before they disrupt manufacturing performance.
Supply and Documentation Readiness: GMP success depends on more than synthesis alone. Raw material qualification, change control awareness, batch records, traceable analytical outputs, and release documentation all affect outsourcing confidence and program continuity. We structure manufacturing projects so technical execution and documentation evolve together rather than as separate workstreams.
Scale-Up Decision Making: Buyers often need to determine whether a sequence is ready for engineering scale, GMP manufacture, or further optimization. Our process assessment approach draws on large-scale oligonucleotide synthesis logic and manufacturing feasibility review to clarify the best next step for each oligonucleotide program.
Our GMP oligonucleotide manufacturing service is designed for teams that need a technically coordinated partner across process development, synthesis, purification, quality control, and release support. We help clients reduce handoff risk between chemistry development, manufacturing execution, and analytical review while keeping project scope aligned with molecule complexity and supply objectives.
Whether your program involves antisense oligonucleotides, siRNA-related strands, aptamers, splice-switching constructs, or modified DNA/RNA sequences, we build manufacturing plans around real project variables such as sequence length, backbone chemistry, impurity profile, scale target, and documentation needs.
The table below helps buyers match manufacturing scope to sequence complexity, quality expectations, and downstream program needs.
| Manufacturing Track | Primary Objective | Key Technical Focus | Typical Deliverables | Best Fit |
| Feasibility & Route Selection | Confirm whether the sequence is ready for regulated manufacture or requires additional development | Sequence risk review, chemistry fit, impurity expectations, purification feasibility | Technical assessment, development recommendations, preliminary manufacturing strategy | New oligo candidates, complex modifications, first-time GMP transition |
| Process Development Program | Build a reproducible and scalable manufacturing route before full GMP campaign execution | Cycle optimization, deprotection strategy, cleavage conditions, process robustness studies | Development data package, optimized process parameters, scale-up readiness guidance | Longer sequences, phosphorothioates, mixed chemistries, impurity-prone constructs |
| GMP Single-Strand Manufacturing | Produce controlled batches of DNA or RNA oligonucleotide drug substance | Solid-phase synthesis, downstream purification, release testing, documentation control | Manufactured bulk oligo, analytical results, batch documentation set | ASO, aptamer, splice-switching, modified single-strand programs |
| Duplex Oligo Program | Manufacture and verify two-strand products requiring defined annealing behavior | Strand matching, individual purity control, annealing strategy, duplex confirmation | Paired strands or duplex product, duplex-related analytical data, release support | siRNA-related and other duplex oligonucleotide formats |
| Modified Oligo Campaign | Execute GMP manufacture for sequences carrying technically meaningful modifications | Modified monomer handling, reaction performance, stability management, impurity control | Modified oligonucleotide batch, chemistry-specific analytical output, process notes | Backbone-modified, terminally labeled, linker-bearing, or mixed-chemistry constructs |
| Conjugated Oligo Workflow | Integrate strand manufacture with downstream conjugation and analytical confirmation | Attachment strategy, purification burden, conjugate integrity, presentation requirements | Oligo intermediate or conjugated product, characterization package, technical review support | GalNAc, lipid, peptide, or other development-stage oligonucleotide conjugates |
BOC Sciences has manufacturing facilities with GMP and ISO certifications. We can provide customized and flexible oligonucleotide GMP production services to meet different GMP-grade production needs. We exceed our customers' expectations by providing exceptional personalized solutions through reproducible systems that meet regulatory standards.
| ISO 13485:2003 & ISO 9001:2008 certified |
|
| Total Product Quality Support |
|
| Logical, Creative Solutions |
|
| Customer-Centric Customization |
|
GMP oligonucleotide manufacturing depends on more than synthesis output alone. It also requires analytical development, purification effectiveness, release testing, and appropriate raw material and process control.
| Quality Control Area | What Is Assessed | Typical Approaches | Why It Matters | When Applied |
| Identity Confirmation | Whether the manufactured oligonucleotide matches the intended sequence and molecular composition | Mass spectrometry, sequence-related confirmation workflows, orthogonal identity review | Prevents incorrect batch assignment and supports confidence in downstream release decisions | Development and GMP release |
| Assay / Content | Relative amount of target oligonucleotide present in the final bulk material | UV-based quantitation, HPLC-linked assay approaches, fit-for-purpose content determination | Supports batch standardization, dosing calculations, and specification alignment | GMP release and comparability review |
| Purity & Related Species | Presence of full-length product relative to shortmers, n-1 species, branching, or other related impurities | RP-HPLC, ion-exchange HPLC, capillary methods, impurity profile review | Purity directly affects batch acceptability, process refinement, and product consistency | Development, scale-up, and release |
| Residual Process Components | Carryover of reagents, solvents, salts, protecting group byproducts, or other process-derived materials | Residual solvent testing, inorganic and organic impurity review, targeted analytical methods | Demonstrates effective downstream control and helps define manufacturing readiness | Process qualification and release planning |
| Duplex / Annealing Status | Whether paired strands are correctly combined and behave as the intended duplex product | Annealing assessment, strand ratio checks, duplex-related analytical confirmation | Important for siRNA-related and other multi-strand oligonucleotide products | Duplex manufacturing programs |
| Conjugate Integrity | Successful attachment and structural consistency for ligand-bearing oligonucleotide constructs | LC-MS review, orthogonal conjugate characterization, purity comparison before and after coupling | Confirms that functionalization did not compromise the target product profile | Conjugated oligo workflows |
| Stability Program Design | How the material behaves under defined storage and handling conditions | Stability protocol planning, time-point testing, trend review, handling recommendation support | Helps clients define shelf-life strategy, shipment conditions, and ongoing material control | Post-manufacture support |
This workflow reflects how development teams typically engage our oligonucleotide specialists for sequence assessment, process development, controlled manufacturing, purification, analytical release, and final documentation handoff.
We review sequence information, modification map, molecule class, target batch requirement, intended quality level, and expected client deliverables. This step ensures the manufacturing plan reflects the actual chemistry burden and avoids under-scoping complex oligonucleotide programs.
Our team evaluates synthesis route feasibility, likely impurity profile, purification burden, analytical scope, and documentation requirements. A project-specific plan is then established for process development, GMP campaign execution, and quality review.
We define synthesis parameters, critical process controls, material requirements, and batch execution logic before manufacturing begins. This stage improves coordination between chemistry operations, quality teams, and client-side CMC stakeholders.
Oligonucleotide manufacturing is executed using the agreed process, followed by cleavage, deprotection, intermediate handling, and downstream purification steps appropriate for the sequence and specification framework. In-process observations are captured to support batch traceability and technical review.
The manufactured material is advanced into identity, purity, assay, and other agreed analytical evaluations. Results are reviewed against batch goals and product expectations so that release discussions are based on structured data rather than isolated test outputs.
We assemble the agreed delivery package, which may include bulk material, analytical results, manufacturing summary information, and supporting technical documentation. Post-delivery communication remains available for follow-up questions, comparability discussion, or next-batch planning.
We built this service for organizations that need more than routine oligo synthesis. Our focus is on controlled manufacturing execution, realistic scale-up logic, and quality-oriented technical support so clients can move complex oligonucleotide programs forward with fewer preventable manufacturing setbacks.
Our GMP oligonucleotide manufacturing service supports multiple development-stage molecule classes that require controlled chemistry, purification discipline, and reliable analytical confirmation. We tailor the manufacturing strategy to the structural and operational demands of each oligonucleotide format rather than forcing all projects into a single workflow.
If your team is preparing a GMP oligonucleotide program and needs a partner who understands sequence-dependent manufacturing risk, purification tradeoffs, analytical release logic, and documentation expectations, we can help. Our service model is designed for biotech companies, pharmaceutical development teams, and research organizations that need controlled oligonucleotide manufacturing backed by practical process thinking and clear technical communication. From feasibility review and process development to manufacturing execution, quality testing, and final handoff, we support oligonucleotide projects with the rigor required for advanced development. Contact us to discuss your GMP oligonucleotide manufacturing requirements.
BOC Sciences can produce DNA, RNA, antisense oligonucleotides, siRNA, mRNA, aptamers, CpG oligos, sgRNA for CRISPR, and catalytically active oligonucleotides with full GMP compliance.
Through strict quality control, HPLC purification, and controlled cleanroom production, every batch is verified for sequence accuracy, purity, and reproducibility.
Various conjugates can be produced, including peptide, antibody, protein, GalNAc, lipid, enzyme, nanoparticle, polymer, and CPP conjugations to support research and molecular applications.
Loading ......
